Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | RHEB | Q15382 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.46 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7516682 | 0.81 | RHEB (0.51) | RHEBPPARGMAPTPTGDR2CHEK2 | |
| SCHEMBL9570559 | 0.73 | MAPT (0.83) | ALDH1A1NPSR1PPARGMAPTMAOA | |
| SCHEMBL30943399 | 0.71 | RHEB (0.69) | ALDH1A1RHEBMAPTCHEK2 | |
| SCHEMBL10736415 | 0.71 | RHEB (0.69) | ALDH1A1RHEBMAPTCHEK2 | |
| Iodide SCHEMBL27236943 | 0.70 | RHEB (0.67) | ALDH1A1RHEBMAPTCHEK2 | |
| SCHEMBL2715938 | 0.69 | RHEB (0.71) | RHEBCHEK2 | |
| SCHEMBL2714424 | 0.69 | RHEB (0.71) | ALDH1A1RHEBCHEK2 | |
| SCHEMBL7516823 | 0.69 | IGF1R (0.56) | RHEBPIK3CAMAOACISD1MAOB | |
| SCHEMBL7516825 | 0.69 | IGF1R (0.56) | RHEBPIK3CAMAOACISD1MAOB | |
| SCHEMBL290413 | 0.69 | MAPT (0.75) | ALDH1A1NPSR1PPARGMAPTMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6452014-B1 | THIAZOLIDINEDIONE COMPOUNDS | GERON CORPORATION | 2002-09-17 | — | — | US | disclosed |
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
| WO-2002051409-A1 | TELOMERASE INHIBITORS AND METHODS OF THEIR USE | GERON CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120144-A1 | Telomerase inhibitors and methods of their use | TERT, TERF2, POT1 | ALDH1A1 786/4885NPSR1 4881/4885RHEB 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.